Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

@360 seems to be support?

360ish yep, unless 'I should have gone to specsavers'.

And Peel Hunt today 710p. I'm seeing consensus tp 577p

Been well oversold throughout the year I reckon.

Clinigen Acquires Ethyol

RNS


RNS Number : 5595P

Clinigen Group plc

20 August 2014








Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

Clinigen Specialty Pharmaceuticals division expands to five products

Burton-on-Trent, UK - 20 August 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol® (amifostine) from AstraZeneca.

Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.

In 1995, the US Food and Drug Administration (FDA) granted Ethyol a New Drug Application ('NDA') and in 2013, Ethyol revenue was approximately $4.9million.

This is the second product Clinigen has acquired from AstraZeneca (the first being the anti-viral Foscavir® in 2010), and the Group's third oncology support product adding to Cardioxane® and Savene® bringing the Specialty Pharmaceuticals portfolio to five products in total.

Under the terms of the agreement, Clinigen will assume full responsibility for the distribution of the product with immediate effect. AstraZeneca, working closely with Clinigen, will continue to manufacture the product whilst the NDA and Investigational New Drug ('IND') authorizations are transferred and the technical transfer to a third party manufacturer is completed. The acquisition will be paid for in milestone related stage payments linked to the transfer of manufacturing. The financial terms of the agreement are not disclosed.

Peter George, Chief Executive Officer, Clinigen Group, said: "I am very pleased to be working with the AstraZeneca team again. In acquiring Ethyol, as well as bringing our total number of products to five, we now have a portfolio of three oncology support products, adding to Cardioxane® and Savene®. This acquisition is in line with our stated strategy of acquiring niche, hospital-only therapies which have the potential to save and improve the lives of critically ill patients. Ethyol was originally identified through our acquisition database of large pharma product candidates as a very good fit for Clinigen's business model; whilst it was one of the original 12 targets and took some time to close, it is further evidence that the Clinigen model works."

- Ends -

Clinigen - Acquisition
Today (2014-08-20 11:23:08)Print this Article
by James Faulkner

Clinigen (CLIN), the specialty pharmaceuticals and services company, has announced the acquisition of the global rights to the oncology support therapy, Ethyol (amifostine) from AstraZeneca. Ethyol is a cytoprotective (cell protecting) drug indicated as an adjuvant therapy (i.e. one that modifies the effects of other agents) to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer.

It also reduces the cumulative renal (kidney) toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer. In 2013, Ethyol revenue was approximately $4.9 million.

Under the terms of the agreement, Clinigen will assume full responsibility for the distribution of the product with immediate effect. AstraZeneca, working closely with Clinigen, will continue to manufacture the product whilst the NDA and Investigational New Drug (IND) authorisations are transferred and the technical transfer to a third party manufacturer is completed. The acquisition will be paid for in milestone related stage payments linked to the transfer of manufacturing. The financial terms of the agreement were not disclosed.

Assessment...

We see it as a positive that Clinigen continues to reduce its reliance on its Foscavir product, especially given the recent weakness seen in this area. Ethyol is the second product Clinigen has acquired from AstraZeneca (the first being the anti-viral Foscavir in 2010), and the group's third oncology support product adding to Cardioxane and Savene bringing the Specialty Pharmaceuticals portfolio to five products in total.

Although we are disappointed by the lack of financial details in today's announcement, if Clinigen can come anywhere close to replicating the success of Foscavir with Ethyol shareholders could see decent returns. Clinigen acquired Foscavir for £9.15 million - a price to sales ratio of 2 times - from AstraZeneca in early 2010. Through its local knowledge and global reach Clinigen has successfully increased pricing around threefold in most countries, has sought (and started to receive) additional regulatory approvals, and is broadening the product's geographic footprint. Sales have grown rapidly from £4.6 million in 2009 to £21.7 million in FY2012.

We retain our belief that Clinigen has a unique combination of businesses that delivers a whole greater than the sum of the parts, which sets it in good stead to realise its ambition of becoming the number one global provider of CTS and GAP services and a major global specialty pharmaceutical company. Furthermore, the cash generative nature of the business means that acquisitions, for the most part, should be able to be funded internally from cashflow.

Valuation...

House broker Numis has noted the potential for "over 100% upside to its 5-year forecasts", should the company meet its stated ambition to become the market leader in both CTS and GAP through organic growth, and to add a further 5-7 specialty pharmaceutical (SP) products over the next 3-5 years (it has now added two since we tipped the shares in April 2013). In this context, we believe the current rating of c.15.1 times 2015 consensus forecast earnings looks like good value, especially when one factors in the rapid earnings growth anticipated over the foreseeable future (PEG <1).

Key risks include further margin erosion, acquisition risks and revenue visibility. We believe recent share price weakness has been overdone, and that the current valuation is well underpinned by the combination of a strong and unique business model, rapid earnings growth and upgrade potential. We therefore keep our stance at 'buy', at 415p.

Clinigen cancer drug acquisition keeps plan on track
Pharmaceutical company Clinigen (CLINC) has added to its cancer care portfolio after the purchase of a chemotherapy drug from AstraZeneca.

Peel Hunt analyst Stefan Hamill retained a ‘buy’ recommendation and increased the target price from 690p to 710p following the purchase of the drug, which reduces the side effects of chemotherapy. Shares jumped 3.7% yesterday on the news to 416.1p.

‘Clinigen’s acquisitions of Ethyol from AstraZeneca fits well into the portfolio, bringing its cancer supportive care portfolio to three and its total portfolio to five products, representing further execution of the plan laid out at initial public offering, when it had just one,’ he said.

‘We factor in modest numbers for Ethyol in advance of an update on the portfolio strategy at the prelims, seeing 3% earnings per share accretion from full year 2016, and moving our valuation up to 710p.’

Clinigen Group: N+1 Singer ups target price from 439p to 488p and keeps a buy recommendation.

2 Sep Oriel... 650.00 Buy

Looks ready to break that 450p level tomorrow!

Could well be tipped this weekend by SCSW, they should have something to say about the new drug.

Notice of Results

RNS


RNS Number : 8184Q

Clinigen Group plc

04 September 2014






Clinigen Group plc

Notification of Full Year Results Date

Burton-on-Trent, UK - 04 September 2014 - Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its full year results for the year ended 30 June 2014 on Wednesday, 24 September 2014.

A group analyst briefing will be held at 09:30am BST on Wednesday, 24 September 2014 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

- Ends -

Tipped in today's Investors Chronicle.

Wondered why it was going so strong. cheers Greyhound.

Hopefully tip sheet article this weekend aswel.

The I. C. article;

Buy ahead of Clinigen re-rating
Bull points
High margins Undervalued Experienced management Strong order book
Bear points
Lumpy revenue stream Disappointing 2013
After listing in late 2012, pharmaceutical group Clinigen (CLIN) fast become the darling of London’s junior Aim market. The listing price – 164p
– surged to 690p early this year but some disappointments in half-year results in February led to a substantial share price fall. But with strong full-year numbers looking likely when the company reports its figures later this month, we think there is now considerable ground to make up on the upside. Investors therefore have a second opportunity to buy the stock, this time at a significant discount to 2013 levels.
There are two main reasons Clinigen won rapturous support from investors when it arrived on the London Stock Exchange. The clinical trials market into which Clinigen supplies third-party material is growing at about 15 per cent a year. Secondly, Clinigen’s management had a proven track record in understanding the complex regulation surrounding specialist access to certain drugs – encompassed by its global access programme (GAP) division.
But at the start of 2014, when Clinigen released half-year results for the six months to December, concerns started to build about the shares overheating. The clinical trial supply (CTS) division – responsible for more than 64 per cent of first-half sales – revealed a 13 per cent fall in sales to £39.5m, and it didn’t help that management admitted that a near four percentage point rise in the CTS gross profit margin – to 16.5 per cent – was ‘unsustainable’. Consequently, the shares crashed 17 per cent on the morning the news came out.
But the company still holds substantial promise for future growth and increasing shareholder returns. The specialty pharmaceuticals division, which provides a solid backbone and accounted for just over half gross profits for the first six months of the year, is still in an early stage of development, with management aiming to add six new drugs over the next three to five years. Meanwhile, the CTS segment is forecast to grow 5 per cent in 2015, and GAP, which accounted for 16 per cent of first-half sales, continues to be Clinigen’s fastest-growing division.
Encouragingly, chief executive Peter George says the lumpy nature of the CTS business and the drop in half-year sales was solely the result of strong comparative figures last year, which included a large number of low-margin anti-viral study sales. He also believes an overdependence on CTS revenues as the bulk of sales will soon be a thing of the past.
A bullish trading update released at the end of July has already begun the re-rating of the stock. In it, Clinigen said it expects like-for-like sales growth of more than 7 per cent for 2014, with total revenues of no less than £126m. The GAP division is expected to report 50 per cent sales growth, and CTS should see revenues up more than 11 per cent in the second half compared with the first half.
Continued improvement in gross margins across all the divisions also contributed to a 17 per cent improvement in underlying cash profits as at the end of June, suggesting full-year results should beat analysts’ expectations. Such a solid performance could be down to lower operational costs, and the keen prices paid for two newly acquired speciality pharma drugs: Cardioxane and Savene. And management says there is also potential in Clinigen’s new business pipeline for CTS and GAP, which broker N+1 Singer puts at about £200m.
Come the 2014 annual results on 24 September, investors should glean further clarity on Clinigen’s new business pipeline and how the new speciality pharma products will help drive growth. This could provide the re-rating catalyst the stock needs. We think investors would do well to boost their stake in Clinigen while the shares trade on 16 times 2015 earnings. Buy. HR

After losing its ‘hot stock’ status at the time of its half-year results in February, Clinigen looks set to re-rate

Cheers g. :-)

Clinigen Launch Antibiotic, Vibativ in Europe

RNS


RNS Number : 0710S

Clinigen Group plc

18 September 2014






Clinigen Group launches New First-in-Class Antibiotic VIBATIV® (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe



Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV® (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.



In March 2013, Clinigen, in-licensed V IBATIV® from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe.



VIBATIV® is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.[1]The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV® may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.[2] As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA.



30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.[3] There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria.









"HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV® is therefore very good news for Europe."



"The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection."



- Ends -

Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe
Date : 18/09/2014 @ 16:15
Source : RNS Non regulatory
Stock : Clinigen (CLIN)
Quote : 463.75 2.0 (0.43%) @ 16:20
HOME » LSE » LSE » Clinigen share price

Clinigen Group plc Clinigen Launch Antibiotic, Vibativ in Europe
Share On Facebook Print
Alert
TIDMCLIN

Clinigen Group plc

18 September 2014

Clinigen Group launches New First-in-Class Antibiotic VIBATIV(R) (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe

Burton-on-Trent, UK - 18 September 2014 - Clinigen Group plc ('Clinigen' or the 'Group') (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV(R) (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia - HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.

In March 2013, Clinigen, in-licensed V IBATIV(R) from Theravance, Inc. for commercialization in Europe, however, at that time the European Marketing Authorisation for the drug was suspended due to stopped operations at the previous manufacturer. Clinigen worked closely with a new contract manufacturer and the relevant European authorities to have the suspension lifted. The European Commission (EC) confirmed this in March 2014 enabling Europe-wide, licensed supply to commence. This will be the first time the licensed product will be available in Europe.

VIBATIV(R) is an innovative treatment for HAP, the most common cause of death among infections acquired in a hospital setting, in that it offers a dual mechanism of action enabling it to kill even drug resistant strains of Staphylococcus aureus.([1]) The drug's dual mechanism of action means that even a strain resistant to one of the mechanisms of action may still be affected by the other mechanism, suggesting that VIBATIV(R) may be less prone to resistance than other antibiotics. HAP caused by MRSA is a considerable unmet need, recognised as a public health priority in the EU. MRSA is estimated to cost EUR380 million every year in extra hospital costs.([2]) As a result of these high costs, both economic and human, there is increasing demand for new tools to combat infections caused by drug-resistant bacterial strains and the availability of new antibacterial agents is recognised as playing an important role in treating MRSA.

30-70% of patients who acquire HAP currently die despite early and appropriate treatment, and the condition places a large burden on healthcare systems.([3]) There is a limited choice of licensed antibiotic therapies able to treat HAP/VAP caused by MRSA and therefore this launch provides an important, alternative, effective agent in the fight against the growing problem of resistance by bacteria.

"HAP caused by MRSA is often more serious and difficult to treat than similar infections with more drug susceptible strains," said Professor Matteo Bassetti, Professor of Infectious Diseases, School of Medicine and Postgraduate School of Infectious Diseases, University of Udine, Italy. "We are increasingly seeing bacteria acquire resistance to antibiotics previously considered last resort treatments; we need more options to treat these extremely serious infections. The widespread availability of a new and effective antibiotic such as VIBATIV(R) is therefore very good news for Europe."

"The emergence of so-called 'super bugs' and increasing resistance among microbes to existing antibiotics has been recognised internationally as a major clinical challenge," said Peter George, Group Chief Executive Officer at Clinigen Group plc. "We are therefore extremely proud to be making this potentially life-saving medicine available across Europe for people who may have no other suitable option to fight a life-threatening infection."

- Ends -

About VIBATIV(R) (telavancin)

VIBATIV(R) is a bactericidal, once-daily, injectable lipoglycopeptide antibiotic with a dual mechanism of action whereby VIBATIV(R) both inhibits bacterial cell wall synthesis and disrupts bacterial cell membrane function. VIBATIV(R) is approved in the United States (US) for the treatment of adult patients with (i) complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including Staphylococcus aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains, and (ii) hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. In September 2011, the European Commission granted Marketing Authorization for VIBATIV(R) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. VIBATIV(R) was discovered and developed by Theravance, Inc., and transferred to Theravance Biopharma, Inc. in connection with the separation of the two companies in June 2014.

In May 2012, the European Commission suspended Marketing Authorization for VIBATIV(R) because the previous single-source drug product supplier did not meet the current Good Manufacturing Practice ("cGMP") requirements for the manufacture of VIBATIV(R). In March this year the European Commission reinstated the marketing authorisation for VIBATIV(R) as consistent product supply was re-established in accordance with European Commission requirements. Theravance Biopharma Antibiotics, Inc. has granted Clinigen exclusive commercialization rights to VIBATIV(R) in the EU and certain other European countries (including Switzerland and Norway).

For further information, for healthcare professionals please visit www.vibativ.eu

About Clinigen

The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP).

Clinigen SP is focused on acquiring its own intellectual property in licensed, niche, hospital-only critical care medicines, increasing the value of these medicines by developing new formulations and indications, then registering and marketing them in defined global markets.

For more information, please visit www.clinigengroup.com

Contact Details

Clinigen Group plc Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer

Shaun Chilton, Chief Operating Officer

Results at the very high end of expectations.

Clinigen Group plc: Underlying EBITDA up 19.8% and EPS up 22% CLINC.L
24 Sep 2014 - 07:10

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140924:nBw236824a BURTON-ON-TRENT, England--(Business Wire)-- Clinigen Group plc (`Clinigen` or the `Group`, AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2014.

Financial highlights

Like for like revenues* on a constant exchange rate basis up 7.5%. Reported revenues up by 3% to £126.6m (FY13: £122.6m)
Gross margin improved in all three operating businesses, increasing to over 30% overall and delivering growth in excess of 17%
Underlying EBITDA** increased by 19.8% to £26.8m (FY13: £22.4m)
Reported pre-tax profits up by 47% to £21.3m (FY13: £14.5m)
Adjusted underlying earnings per share*** up 22% to 24.5 pence (FY13: 20.1 pence) and reported earnings per share up 30% to 19.6 pence (FY13: 15.1 pence)
Cash generation continues to be strong. Net cash of £5.3m combined with the borrowing facility of £35m, provides opportunity for continued expansion.
Final dividend 2.1 pence per share proposed; total dividend 3.1 pence per share (FY13: 2.6 pence per share), up 19%.
Business highlights

Specialty Pharmaceuticals (SP)
Total number of products increased from three to five following the acquisition of two oncology support products; Savene in March 2014 and Ethyol in August 2014.
Suspension of Marketing Authorization lifted for Vibativ and product launched September 2014.
New indications and price increases applied to Foscavir.
Clinical Trials Supply (CTS)
Gross margins returned to 15.1%; deeper penetration of customer base with requests to supply and product sourced both up more than 30%.
New exclusive supply agreement signed.
Global Access Programs (GAP)
58,000 units of drugs shipped to more than 75 countries, an 87% increase, coming from both growth in existing programs and new programs.
Cliniport launched and applied to all programs.
Like for like sales represent revenues adjusted for Foscavir stock fill (£3m) in FY13. ** Underlying EBITDA is defined as earnings before interest, tax, depreciation and amortization excluding share based payments. *** Underlying earnings exclude share based payments, and are adjusted for amortization and associated tax.
Peter George, Chief Executive Officer, Clinigen Group,said "We have had another strong year of growth, with all three operational businesses increasing their contribution.

"Organic business has increased in both CTS and GAP, with a significant improvement in margins for CTS. In SP, we have seen steady growth in in-market sales from Foscavir and revenue streams beginning to come on board from Cardioxane and newly acquired Savene. Vibativ has been revitalized and, in September 2014, launched into the European market. The acquisition of Ethyol brings the total SP drug portfolio to five.

"In the next financial year, the priorities for the Group are two fold; the revitalization of SP`s dexrazoxane asset portfolio (Cardioxane and Savene) and the strengthening of our global capabilities, particularly in pharmerging markets.

"Both strategic goals are important to our long term growth and will support our ambition to become a recognized world leading specialty pharmaceutical company with unrivalled global distribution capability for licensed and unlicenced medicines."

-Ends-

For the full release, please visit the Group`s website at www.clinigengroup.com

What they were expecting......note

2013 (A) 2014 (E) 2015 (E)
EBITDA £19.98m £25.00m £28.69m

OUTPERFORMED

Clinigen Group PLC

Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

N+1 Singer
22-09-14 BUY 23.49 21.80 3.00 26.66 24.10 3.30
Peel Hunt LLP
18-09-14 BUY 26.05 23.42 3.50 28.97 25.99 4.00
Edison
18-09-14 None 19.40 18.30 2.80 22.20 20.90 3.10
Numis Securities Ltd
17-09-14 BUY 26.00 23.50 3.39 29.00 26.10 4.03
Investec Securities
04-09-14 BUY 25.10 22.61 4.00 29.80 27.45 4.43
Westhouse Securities
10-04-14 BUY

2014 2015
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Consensus 25.15 22.82 3.29 28.60 25.38 3.77
1 Month Change -0.34 -0.16 -0.15 -0.08 -0.60 -0.35
3 Month Change 0.54 1.24 -0.04 -0.86 -1.10 -0.24

GROWTH

2013 (A) 2014 (E) 2015 (E)
Norm. EPS 107.38% 26.45% 11.22%
DPS % 449.00% 14.51%

INVESTMENT RATIOS

2013 (A) 2014 (E) 2015 (E)
EBITDA £19.98m £25.00m £28.69m
EBIT £18.10m £m £m
Dividend Yield 0.13% 0.71% 0.81%
Dividend Cover 30.08x 6.93x 6.73x
PER 25.79x 20.39x 18.34x
PEG 0.24f 0.77f 1.64f
Net Asset Value PS 14.21p 78.80p 98.60p